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Abstract In healthy subjects some tissues in the human body display metabolic
flexibility, by this we mean the ability for the tissue to switch its fuel source be-
tween predominantly carbohydrates in the post prandial state and predominantly
fats in the fasted state. Many of the pathways involved with human metabolism
are controlled by insulin, and insulin-resistant states such as obesity and type-2
diabetes are characterised by a loss or impairment of metabolic flexibility.
In this paper we derive a system of 12 first-order coupled differential equations
that describe the transport between and storage in different tissues of the human
body. We find steady state solutions to these equations and use these results to
nondimensionalise the model. We then solve the model numerically to simulate
a healthy balanced meal and a high fat meal and we discuss and compare these
results. Our numerical results show good agreement with experimental data where
we have data available to us and the results show behaviour that agrees with
intuition where we currently have no data with which to compare.
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21 Introduction
The human diet consists of a mix of carbohydrates and fats delivered in a discontin-
uous manner whilst the human body is constantly expending energy. To deal with
this discontinuous supply of energy from the diet, human physiology has evolved
mechanisms to manage the transport, storage and utilisation of carbohydrates and
fats between the different tissues of the body.
In lean healthy subjects skeletal muscle displays metabolic flexibility, by this
we mean that the body is able to switch its fuel source between predominantly
carbohydrates in the post prandial, insulin stimulated, state and predominantly
fats in the fasted state. The main regulatory hormone involved in metabolism is
insulin, and because of this, insulin resistant states such as type 2 diabetes and
obesity are characterised by this loss of metabolic flexibility [1,2].
Insulin resistance or insulin deficient states can be generalised into three cat-
egories: (i) abnormal β-cell secretory product, resulting in lower levels of insulin
being produced by the β-cells of the pancreas, that is, insulin insufficiency; (ii)
insulin antagonists in the blood plasma, either due to counterregulatory hormones
or due to non-hormonal bodies that either affect insulin receptors or alter insulin
signalling effectiveness; (iii) the target tissue being defective in insulin action, due
either to insulin receptor defects or to defects in the effector systems. The third of
these causes is of most interest to us as this form of insulin resistance is common
in some obese and all type 2 diabetic subjects, although early phase insulin secre-
tion is inhibited in some type 2 diabetic subjects [3,4]. Both obese and diabetic
subjects demonstrate a reduced rate of plasma glucose disposal and a higher than
normal basal glucose level [3–5]. In the case of type 2 diabetes this can be par-
tially explained by the fact that hepatic glucose uptake is impaired [4,6] and the
suppression of hepatic glucose output by insulin is reduced [7]; also skeletal mus-
cle glucose uptake is known to be impaired in type 2 diabetes [8]. Similarly, with
non-diabetic obese subjects there is reduced hepatic glucose output suppression
from insulin [3,5] and reduced skeletal muscle glucose uptake [9]. It has also been
shown that insulin resistant subjects can have increased hepatic lipogenesis, re-
sulting in larger changes in hepatic triglyceride concentrations in the post prandial
state which is counter intuitive as it is an insulin stimulated pathway; however,
it was also shown that the insulin resistant subjects had a much greater reduc-
tion in muscle glucose uptake indicating that insulin resistance affects different
tissues to different degrees [10] with the liver being less severely affected [11]. It
is not just glucose metabolism that is affected by insulin resistance, it also affects
adipose tissue with reduced insulin suppression of free fatty acid release common
in obesity [9]. Insulin resistant subjects also show reduced adipose tissue triglyc-
eride clearance and reduced skeletal muscle triglyceride clearance [13]. Fatty liver
disease is a large area of interest currently as it is closely related to obesity and
insulin resistance. Although it has been shown that there is a strong correlation
between obesity and fatty liver disease [14] it is not known if fatty liver disease
is the cause or effect of insulin resistance. It has been shown that post-prandial
hepatic triglyceride release is higher in people with fatty liver disease than healthy
people although the basal secretion rate is the same, indicating that it is not a
higher fat presence in the liver which causes the increased output but rather insulin
resistance [15].
3Although there has been much work published on mathematical modelling of
human metabolism much has focused on single tissues or a limited number of
substrates and, in some cases, on metabolism at a cellular level. Glucose-insulin
metabolism has been extensively investigated with many models describing the
effect of insulin supply on glucose metabolism [22–25] and conversely the effects of
a controlled glucose supply on insulin dynamics [26]. More complex models have
also been proposed [27–29,43] which although detailed are still limited to glucose-
insulin metabolism. There are also models focusing on the metabolism of a variety
of lipoproteins in the body and the transport of and conversion between them
[30]. Other models describe specific types of lipoprotein and their competitive
uptake in the liver [31–33]. Models of skeletal muscle metabolism, particularly
in terms of energy balance, have also been proposed [34,35] however these are
restricted to skeletal muscle and ignore the rest of the body. Some very detailed
although very computational models have also been proposed covering skeletal
muscle [46,47] and whole body metabolism [44]. There has also been simpler, more
analytical, models proposed to describe whole body metabolism of carbohydrates,
fats and proteins on long time scales although these tend to focus on energy
balance and weight gain [36–42]. A recent PhD thesis developed four detailed,
separate, models of metabolism covering glucose-fat interactions, hepatic glucose
metabolism, postprandial lipid metabolism and adipose tissue distribution [45].
In this paper we develop a compartmental mathematical model to describe the
transport, storage and utilisation of glucose and fats in the human body covering
many of the different tissues. In particular we pay close attention to the blood
plasma, the liver and skeletal muscle and we include terms which model the rest of
the tissues in the human body. We aim to produce a model describing whole body
metabolism as opposed to more detailed models which focus on a single metabolic
subsystem. As such we take a more simplified approach to modelling the complex
physiological process in the human body but still retain enough detail to produce
meaningful results. Once we have formulated our model in section 2; in section
3 we find steady state equations in the fasted state where steady concentrations
are applicable, and use these to nondimensionalise the model, details of which
are given in Appendix B. In section 4 we refer to the experimental literature to
derive parameter values for the model. Finally we generate numerical results to
the system of equations subject to realistic simulated meals in section 5 and in
section 6 we draw conclusions.
2 Mathematical Model of Metabolism
In this section we formulate a mathematical model describing human metabolism
and the dynamics of metabolic flexibility. We take account of the substrates glu-
cose, glycogen, triglyceride (TAG), free fatty acids (FFA) and insulin in multiple
compartments, of blood plasma, liver and skeletal muscle and we assume adipose
tissue to be an unlimited source of FFA. Since we are concerned with how con-
centrations evolve over a 12-14 hour period this is quite reasonable. We model the
synthesis and transport between compartments of each substrate. We assume the
usage of glucose by the tissues and organs not modelled to be linearly dependent
on the amount of each substrate in the blood plasma and that fat usage by the
rest of the body is negligible. We derive the model one compartment at a time
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Fig. 1 Diagram showing the input and transportation of glucose, FFA and TAG in the blood
plasma, not including utilisation by the rest of the body, with the rate of flux for each pathway
shown.
and start with the blood plasma as this acts as the main transport medium for
substrates between the different organs and tissues of the body and no synthesis
of glucose, FFA or TAG occurs in the plasma.
Following ingestion of a meal, glucose and TAG are absorbed from the gut
into the blood plasma and we will use this as the input for our model. As well as
this absorption from the gut, FFA are released, at an insulin-inhibited rate, into
the blood plasma from stores in adipose tissue. The presence of glucose and, to a
lesser extent, FFA in the plasma stimulates the pancreas to produce and secrete
insulin. We assume that insulin secretion dependence on FFA is small and model
it by a linear dependence. Experimental data showing pancreatic insulin secre-
tion rate compared to plasma glucose concentration [16] suggests a Hill function
models the glucose-dependence. Whilst glucose concentrations at the higher end
of the data are only observed, in vivo, in cases of hyperglycemia, we include the
saturating effect whereby the insulin production term has some maximum value
even at extreme glucose levels. Hence, with these assumptions we arrive at our
first equation, modelling plasma insulin concentration by
Vb
dI
dt
= k1 + k2erf((Gb − v)/c) + kIAAb − λII, (1)
where the first two terms represent the saturating dependence on plasma glucose
(Gb), the third term represents the linear dependence on plasma FFA (Ab) and
the final term represents the linear decay of plasma insulin.
We now turn our attention to the uptake from and secretion to the plasma
of glucose, TAG and FFA. The pathways we will now discuss are shown in fig-
ure 1. Glucose in the plasma may be taken up into skeletal muscle v ia two glu-
cose transporters, the GLUT1 insulin-independent and GLUT4 insulin-dependent
transporters. Other tissues of the body, such as the brain and the kidneys, use
glucose as their energy source; we model this effect with the usage term SGGb in
5the equations below. Glucose can also be taken up into and secreted by the liver,
the uptake into the intracellular compartments of the liver, and the release back
into the plasma, is handled by the GLUT2 insulin independent transporter and
as such is entirely driven by concentration gradients. For this reason we make a
simplification that we can ignore this step and instead we take account of what
can happen to hepatic intracellular glucose. The storage of glucose in the liver
as glycogen is mediated by insulin-stimulated enzymes and the liver has a finite
storage capacity. The breakdown of glycogen back into glucose is mediated by
insulin-inhibited enzymes. As well as storage as glycogen, glucose in the liver can
be used to synthesise FFA in the liver v ia the pathways of glycolysis and subse-
quently lipogenesis, there are many steps in these pathways; however, we make
use of the fact that each step in the pathways is insulin-stimulated and simplify
this to a single insulin-stimulated step. It is worth noting that no glucose released
from the breakdown of glycogen is used in FFA synthesis as the the breakdown of
glycogen happens predominantly in the fasted, low insulin state, when the insulin-
stimulated pathway of hepatic FFA synthesis will be inactive, allowing our earlier
simplification of ignoring intracellular glucose to remain valid. FFA in the plasma
may be taken up into the liver and released back as well as being taken up into
skeletal muscle and is handled by an insulin-independent fatty acid transporter.
As well as being absorbed from the gut TAG can be released into the plasma
from the liver, this release is inhibited by insulin and is somewhat dependent on
liver fat content, in that at lower liver fat levels secretion is reduced; however this
secretion rate does not increase drastically at high liver fat levels. TAG in the
plasma can be taken up into adipose tissue and skeletal muscle. Although TAG
molecules are too large to be taken across the cell membrane they are bound to the
cell walls and broken down by the enzyme lipoprotein lipase into FFA before being
taken up into the cell. Lipoprotein lipase is thought to be dependent on insulin in
adipose tissue and so we model the breakdown and uptake of TAG on this pathway
as being both insulin-independent and insulin-dependent, however lipoprotein li-
pase is not insulin stimulated in skeletal muscle. Using these assumptions we arrive
at the equations
Vb
dGb
dt
=
„
βG
1 + kGLI2
«
f1(YL)− SGGb − kG(1 + kGII)Gb − kLIGbf2(YL)
−kALIGb + FG(t), (2)
Vb
dTb
dt
=
„
βT
1 + kTLI
«
f3(TL)− kTTb − kTA(1 + kAII)Tb + FT (t), (3)
Vb
dAb
dt
=
βA
1 + kAAI2
− kAAb − kBLAb + kLBAL. (4)
Equations (2)–(4) describe the concentrations of plasma glucose, TAG and
FFA respectively where YL, TL and AL denote the concentrations of hepatic glu-
cose (stored as glycogen), TAG and FFA respectively. We have introduced the
dimensional parameter Vb = blood volume. The nondimensional functions f1, f2
and f3 are introduced so that the uptake and release of glucose and the release of
TAG from the liver is dependent on how much is in the liver. In the case of f1 the
rate of release of glucose from the liver should depend on insulin with the main
dependence on hepatic glycogen being that the release should be slow or switched
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Fig. 2 Diagram showing the input and transportation of glucose, FFA and TAG in the liver
with the rate of flux for each pathway shown.
off when the store is almost empty. Similar properties hold for the hepatic TAG
release and the function f3. In the case of f2 the uptake of glucose by the liver
should be mostly dependent on plasma glucose and insulin with the dependence
on hepatic glycogen to slow or shut off completely the uptake when the liver is
almost full. Hence we define these functions by
f1(YL) =
YL
Y0 + YL
, f2(YL) =
Ymax − YL
Y0 + Ymax − YL
, f3(TL) =
TL
T0 + TL
, (5)
where Ymax denotes the maximum amount of glycogen the liver can store and Y0
and T0 are small parameters. The final terms in equations (2) and (3) model the
glucose and TAG absorbed by the gut following ingestion of a meal and are given
by
FG(t) =
θGt
B2G
e−t
2/2B2
G , FT (t) =
θT t
B2T
e−t
2/2B2
T . (6)
These will act as our control inputs for the model and we are free to choose the
parameters in these functions, θG and θT control the magnitude of the substrates
entering the blood stream and BG and BT control the timescale for the release
into the blood.
We now derive the equations for the liver, the pathways we discuss are shown
in figure 2. As mentioned before, glucose from the plasma can be taken up into the
liver and either stored as glycogen or used to synthesise fatty acids. Fatty acids
from the plasma contribute to the hepatic FFA pool, with insulin independent
uptake to and release from the liver. This FFA can be converted to fatty acetyl-
CoA, v ia an insulin-independent process which is, in turn, either converted to
TAG and stored in the liver, or oxidised to create ketone bodies. We make a
simplification here in that we do not take account of the concentration of fatty
acetyl-CoA but rather we will introduce two sink terms into the equation for
hepatic FFA, to represent the FFA oxidised into ketone bodies and that stored
as TAG. The storage as TAG is driven by an insulin-stimulated pathway and
7the oxidation to ketone bodies is primarily stimulated by glucagon. Currently our
model does not include glucagon; however, it has been shown that glucagon and
insulin are in general inversely related such that at high levels of insulin there is
a low level of glucagon and v ice versa [17, Ch. 5]. Hence we model this glucagon-
stimulation as insulin inhibition. As mentioned before, TAG stored in the liver is
released back into the plasma at an insulin-inhibited rate. Using these assumptions
we arrive at the equations
Vl
dYL
dt
= kLIGbf2(YL)−
„
βG
1 + kGLI2
«
f1(YL), (7)
Vl
dAL
dt
= kALIGb −
SLAL
1 + kASI
+ kBLAb − kLBAL − kTHIAL, (8)
Vl
dTL
dt
= kTHIAL −
„
βT
1 + kTLI
«
f3(TL). (9)
Equations (7)–(9) describe the concentrations of hepatic glucose (stored as glyco-
gen), FFA and TAG respectively. As with the equations for plasma concentrations
(2)–(4) we have introduced the dimensional parameter Vl = liver volume. We use
the same units for our glycogen concentration variables as for glucose; thus glyco-
gen is measured in effective, or equivalent, amount of glucose that can be stored
in that form.
We complete the compartmental model by deriving equations for skeletal mus-
cle. As well as modelling the uptake, storage and usage of glucose and FFA by
the skeletal muscle we take account of energy expenditure since in skeletal muscle
this has a large effect on the metabolism in the skeletal muscle. To model skeletal
muscle energy expenditure we define a new variable, P , which is related to skeletal
muscle AMP concentration; although not actually AMP concentration, it acts as
a measure of flux through the skeletal muscle oxidative pathways. We assume that
P decays linearly and is decreased by oxidation with glucose or FFA in the skeletal
muscle to create ATP, with glucose oxidation being insulin-stimulated and FFA
oxidation insulin-independent. Using these assumptions we derive
Vs
dP
dt
= µ− λPP − γaMAAmP − γgMGPIGm. (10)
The parameter µ acts as our measure of energy expenditure and is a control input
for our model. As a first approximation we could assume a constant production
of AMP from ATP, however, this is unphysical, as there is only a limited amount
of ATP, ADP, and AMP available, so as AMP rises, ATP decreases, and the rate
of production of AMP would also decrease. This effect is modelled in a simplistic
way by the combined effect of µ and λ. The nondimensional parameters γa and
γg are the number of P molecules used in FFA and glucose oxidation respectively.
The dimensional parameter Vs = skeletal muscle volume.
We now derive equations for skeletal muscle glucose, glycogen, FFA and TAG.
As before the pathways we will consider are shown in figure 3. As mentioned
earlier, glucose is taken up from the plasma at insulin-stimulated and insulin-
independent rates, FFA is taken up from the plasma at an insulin-independent
rate and TAG is taken up into skeletal muscle by being broken down into FFA at
an insulin-independent rate. Once inside skeletal muscle, glucose and FFA, as well
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Fig. 3 Diagram showing the input and transportation of glucose, glycogen , FFA and TAG
in skeletal muscle with the rate of flux for each pathway shown.
as being oxidised, can be stored as glycogen and TAG respectively, to be released
later, when needed. We assume the rate of storage and release of both FFA and
glycogen are regulated in the same way, with storage being insulin-stimulated and
AMP-inhibited and release being AMP-stimulated and insulin-inhibited. Using
these assumptions we arrive at the equations
Vs
dGm
dt
= kG(1 + kGII)Gb −MGPIGm − kY
„
1 + kY II
1 + kY PP
«
Gm +
kCPPYm
1 + kCII
,
(11)
Vs
dYm
dt
= kY
„
1 + kY II
1 + kY PP
«
Gm −
kCPPYm
1 + kCII
, (12)
Vs
dAm
dt
= kTTb + kAAb −MAPAm − kX
„
1 + kXII
1 + kXPP
«
Am +
kDPPTm
1 + kDII
,
(13)
Vs
dTm
dt
= kX
„
1 + kXII
1 + kXPP
«
Am −
kDPPTm
1 + kDII
. (14)
Equations (11)–(14) describe the concentration of skeletal muscle glucose, glyco-
gen, FFA and TAG respectively. As with hepatic glycogen, the concentration of
skeletal muscle glycogen is actually the concentration of potential glucose stored as
glycogen and the concentration of skeletal muscle TAG is actually the concentra-
tion of potential FFA stored as TAG. The terms MGPIGm in (11) and MAPAm
in (13) describe the use of glucose and fatty acids in the conversion of AMP (and
ADP) to ATP, which is then a source of energy for muscle’s activity. Protein could
also provide a component of the energy required for ATP production, but since
our model does not include protein metabolism, we have ignored such effects in
this work.
In summary, we have derived twelve first-order coupled differential equations
along with 53 dimensional parameters which describe our model. All parameter
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Fig. 4 Diagram of the biochemical reaction network modelled in the rest of this paper. Dashed
boxes indicate the different compartments of the model with the liver at the top, the blood
plasma in the middle and skeletal muscle at the bottom.
values are given in table 1 along with a brief description of the parameter and a
reference to its source where applicable. We summarise the overall model and the
interactions between compartments in figure 4.
3 Steady State
The steady state we are interested in is the state reached after a 12–14 hour
overnight fast. Although hepatic glycogen and hepatic triglyceride will not be
at steady state at this time, we assume the stores are sufficiently high that we
may approximate the functions f1, f2 and f3 by 1, in the case of f2 we are also
assuming YL is not close to Ymax (that is, Y0 ≪ Ymax − YL). These assumptions
are reasonable for our steady state as YL will only be near Y0 after a period of
starvation and will only be near Ymax directly after a meal. Steady state values of
variables will be denoted with a superscript “*”.
We start by finding the steady states of equations (2) and (3)
G∗b =
βG
(1 + kGLI∗
2)(SG + kG(1 + kGII∗) + kLI∗ + kALI∗)
, (15)
T ∗b =
βT
(1 + kTLI∗)(kTA(1 + kAII∗) + kT )
. (16)
Next we solve for the steady states of equations (4) and (8). Solving them explicitly
would lead to complicated formulae so we leave the solutions as implicit expressions
10
Table 1 List of dimensional parameters together with brief description of each parameter.
References are given where a parameter is known from the literature. Parameters without a
value given are either eliminated in the nondimensionalisation, are input parameters that we
are free to choose. † The value of the parameter βT is determined in section 4 using the steady
state relations obtained in section 3.
Parameter Description Value Units Reference
MG Glucose oxidation rate 20000 l
3/min3
MA FFA oxidation rate 0.02 l
2/min2
kY glycogen synthesis rate (basal) l/min
kY I glycogen synthesis rate (insulin stimulated) 1000000 l/mmol
kY P glycogen synthesis rate (AMP inhibited) 0 l/mmol
kT muscle triglyceride uptake rate (basal) 6×10
−3 l/min [13]
kG muscle glucose uptake rate (basal) 1.08×10
−1 l/min [18]
kGI muscle glucose uptake rate (insulin stimulated) 1.75×10
7 l/mmol [18]
kCP glycogenolysis rate (AMP stimulated) 0.1 l
2/min2
kCI glycogenolysis rate (insulin inhibited) 0 l/min [17, Ch.4]
SG body glucose consumption rate l/min
µ AMP (P) creation rate 1 mmol/min
λI insulin degradation rate l/min
k1 insulin production rate 6.97× 10−5 mmol/min
k2 insulin production rate 8.36× 10−5 mmol/min
v insulin production (glucose threshold) 9 mmol/l
c insulin production (glucose range) 4 mmol/l
kIA insulin production rate 10
−6 l/min
kA muscle FFA uptake rate constant l/min
βA basal FFA production rate 0.33 mmol/min [13]
βT basal triglyceride production rate 6.75×10
−3 mmol/min †
βG basal glucose production rate 0.57 mmol/min [12]
γa number of P molecules used in FFA oxidation 1
γg number of P molecules used in glucose oxidation 1
λP degradation of P in absence of any other process l/min
kGL insulin inhibition rate for glucose from liver 1.06×10
14 l2/mmol2 [18]
kTL insulin inhibition rate for TAG from liver 2.5×10
6 l/mmol [15]
kAA insulin inhibition rate for FFA from adipose tissue 2×10
14 l2/mmol2 [13]
kTA adipose TAG uptake constant (basal) 1.5×10
−3 l/min [13]
kAI adipose TAG uptake const. (insulin stimulated) 5×10
6 l/mmol [13]
kX muscle TAG synthesis rate constant (basal) l/min
kXI muscle TAG synthesis const. (insulin stimulated) 0 l/mmol [17, Ch.4]
kXP muscle TAG synthesis constant (AMP inhibited) 0 l/mmol [17, Ch.4]
kDP muscle TAG usage constant (AMP stimulated) 0 l
2/min2
kDI muscle TAG usage constant (insulin inhibited) 0 l/mmol [17, Ch.4]
kL liver glucose uptake rate 6×10
5 l2/min2 [12]
Ymax maximum potential glucose stored in liver 310 mmol/l [21]
Vb blood volume 5 l
Vl liver volume 1.8 l [19]
Vs skeletal muscle volume 30 l [20]
kAL rate of conversion of glucose to FFA via glycolysis 2000 l
2/mmol min
kAS insulin inhibition rate for oxidation of hepatic FFA 10
5 l/mmol
kBL rate of uptake of plasma FFA into the liver 0.034 l/min
kLB rate of release of hepatic FFA into blood plasma 0.0059 l/min
kTH rate of conversion of FFA to TAG in the liver 33000 l
2/mmol min
SL rate of oxidation of FFA in the liver 0.01 l/min
BT delay from feeding to triglyceride reaching blood min
BG delay from feeding to glucose reaching blood min
θG amount of carbohydrates in diet mmol
θT amount of triglyceride in diet mmol
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Table 2 List of steady state concentrations for plasma model variables together with reference.
Parameter Description Value Reference
G∗b Plasma glucose 5 mmol/l [17, Ch. 6]
T ∗b Plasma TAG 1 mmol/l [17, Ch. 6]
A∗b Plasma FFA 0.5 mmol/l [17, Ch. 6]
I∗ Plasma Insulin 5× 10−8 mmol/l [17, Ch. 6]
in a form that is useful when we non-dimensionalise
A∗b =
βA
(1 + kAAI∗
2)(kA + kBL)
+
kLBA
∗
L
kA + kBL
, (17)
A∗L =
kALI
∗G∗b + kBLA
∗
b
SL
1+kASI∗
+ kLB + kTHI∗
. (18)
The steady state solution for insulin is governed by a complicated equation
and it is not useful for us to consider the steady state value of this right now as
values are commonly available in the literature.
The steady state solutions for equations (11)–(14) are given by
G∗m =
βGkG(1 + kGII
∗)
MGP ∗I∗(SG + kG(1 + kGII∗) + kLI∗ + kALI∗)
, (19)
Y ∗m = kYG
∗
m
„
1 + kY II
∗
1 + kY PP ∗
«„
1 + kCII
∗
kCPP ∗
«
, (20)
A∗m =
1
MAP ∗
„
βTkT
(1 + kTLI∗)(kTA(1 + kAII∗) + kT )
«
(21)
+
1
MAP ∗
„
βAkA
(1 + kAAI∗
2)(kA + kBL)
«
+
1
MAP ∗
„
kAkLBA
∗
L
kA + kBL
«
,
T ∗m = kXA
∗
m
„
1 + kXII
∗
1 + kXPP ∗
«„
1 + kDII
∗
kDPP ∗
«
. (22)
We can use these equations to find the steady state value for P
P ∗ =
µ− µc
λP
, (23)
where µc is given by
µc =
γAβTkT
(1 + kTLI∗)(kTAI∗ + kT )
+
γGβGkG(1 + kGII
∗)
SG + kG(1 + kGII∗) + kLI∗ + kALI∗
+
γAβAkA
(1 + kAAI∗
2)(kA + kBL)
+
γAkAkLBA
∗
L
kA + kBL
, (24)
and we require µ > µc. The steady state values for plasma substrate concentra-
tions, which are widely available in the literature, are given in table 2.
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4 Parameter Assessment
Our model has a total of around 50 dimensional parameters, of these: 8 are input
parameters which we are free to pick in order to simulate different conditions, 4
are parameters that we can eliminate through nondimensionalisation and the re-
maining are physiological rate parameters which we must either determine from
the literature or, where not known, must choose for ourselves such that the nu-
merical results behave as expected from time courses of experimental data. In this
section we describe how we determine some of the model parameters from data
available in the literature. We will also make use of some of the results in section
3 by enforcing that some of the equations tend to a steady state, from which we
derive a relationship between a group of parameters and the steady state value
of a variable. The steady state values of many of our model variables are well
documented in the literature so rather than using our estimated parameters to
determine the value of the steady state, we will use the well documented steady
state values to eliminate the need for us to find all parameters. The standard units
of our model are mmol/l for concentrations and time is measured in minutes.
Ymax - The liver is known to be able to store approximately 100 g of glucose
as glycogen [21]. Using an approximate liver volume of 1.8 litres [19] this yields a
concentration of 55.5 g/l. Converting this into the standard units of the model we
find Ymax ≈ 310 mmol/l.
kG, kGI , kGL - Meyer et al. [18] studied postprandial glucose homeostasis,
analysing the liver, kidneys and skeletal muscle. Healthy subjects were given a
75 gram glucose meal and blood samples were taken over a period of 270 minutes.
Fasting plasma glucose and insulin was measured at approximately 5 mmol/l and
50 pmol/l respectively and fasting skeletal muscle glucose uptake calculated as
approximately 2 µmol/kg/min. Postprandial results showed peak plasma glucose,
insulin and skeletal muscle glucose uptake after approximately 90 minutes, with
plasma glucose and insulin at approximately 7.5 mmol/l and 300 pmol/l respec-
tively and skeletal muscle glucose uptake at approximately 10 µmol/kg/min. This
skeletal muscle glucose uptake is given in our model by the term kG(1+kGII)Gb/Vb
and as we have data for this rate of uptake, plasma glucose and insulin levels
both at the fasted state and at 90 minutes postprandial we can solve simultane-
ously for the two parameters which gives values of kG ≈ 1.08 × 10
−1 l/min and
kGI ≈ 1.75×10
7 l/mmol. This study also calculated hepatic glucose output and we
use this data to calculate kGL, the magnitude of hepatic glucose output suppres-
sion by insulin. The data calculated hepatic glucose output as 8.34 µmol/kg/min
in the fasted state and as 0.21 µmol/kg/min in the postprandial state. As stated
before we also know the concentrations of insulin at these times and we can pick
our parameter such that the measured increase in insulin levels results in a sup-
pression of hepatic glucose output in agreement with the data. This yields an
estimate of kGL ≈ 1.06× 10
14 l2/pmol2.
βG, kL - Taylor et al. [12] carried out a study into hepatic glycogen storage
in healthy subjects. Three different studies where done order to measure different
rates and concentrations.We will be interested in the data from study A as this had
the most simple protocol. Subjects were fed a liquid meal of approximately 550 kcal
carbohydrates and 150 kcal fat following an overnight fast. Hepatic glycogen levels
were then measured over the next 10 hours using magnetic resonance spectroscopy.
The results showed a steady rise in hepatic glycogen concentration during the
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insulin stimulated postprandial period to near the liver storage limit, followed by
a steady decline in hepatic glycogen over the remainder of the 10 hours. We pick
our parameters such that subject to the same simulated meal our results show
a qualitative agreement with this data, in particular that hepatic glycogen rises
following the meal until almost full followed by a steady decline returning to its
initial value after a 12–14 hour fast. This gives estimates for the parameters of
βG ≈ 0.57 mmol/min and kL ≈ 6× 10
5 l2/mmol/min.
kT , kTA, kAI , βA, kAA - Bickerton et al. [13] carried out a study looking into
fatty acid metabolism in healthy and insulin-resistant men. The study was carried
out after an overnight fast followed by a test meal of 40g fat and 40g carbohy-
drate. Blood samples were taken for 6 hours after ingestion of the meal (initially
every 30 minutes and then every 60 minutes) and results for plasma concentra-
tions recorded as well as a calculation of the rate of clearance of TAG from the
plasma into adipose tissue and skeletal muscle. Comparing the results for skeletal
muscle TAG clearance to the plasma TAG concentration confirmed that a linear
relationship between skeletal muscle TAG uptake and plasma TAG concentration
was a good model. After converting the units of the study (ml/min/100g tissue)
into the units of our model we are able to derive a value for kT by finding the
value of kT /Vb that maps the results for plasma TAG concentration to the results
of skeletal muscle TAG clearance. This gives a value for kT of 6 × 10
−2 l/min.
However the results for adipose tissue TAG clearance show a behaviour that our
current model is unable to simulate and show an immediate spike in adipose TAG
uptake which then returns towards steady state value before raising again later,
coinciding with the peak in plasma TAG levels. The data also shows a third rise
in adipose TAG uptake towards the end of the data at approximately 6 hours
after the test meal when TAG and insulin levels have returned to steady state.
We nevertheless find values for kTA and kAI that produces as good a fit with the
experimental data as possible, in particular our model predicts rates of uptake
within the same range of values as the data. We use the same approach as with
skeletal muscle uptake and take the data for plasma TAG and also insulin and
pick values for the parameters which make the quantity kTA(1 + kAII)Tb/Vb in
good agreement with the experimental data. Using kTA = 1.5 × 10
−2 l/min and
kAI = 5 × 10
6 l/mmol yields results in the same range as the experimental data
however this does not show good qualitative agreement, in particular the third
spike in adipose tissue TAG uptake. Also of use to us from this study is the re-
sults for adipose tissue NEFA (FFA) output. Fasting adipose NEFA output was
measured at approximately 1200 nmol/minute/100g adipose tissue, at which time
plasma insulin was measured at approximately 50 pmol/l. At approximately 120
minutes after the meal was ingested adipose NEFA output reached its minimum
of approximately 200 nmol/min/100g adipose tissue, this coincides with the max-
imum plasma insulin concentration measured, approximately 200 pmol/l. Adipose
tissue NEFA output is given in our model by the term βA/(Vb(1 + kAAI
2)) and
as we have data for this rate of release and insulin levels both at the fasted state
and 120 minutes postprandial we can solve simultaneously for the two parameters
which gives values of βA ≈ 0.33 mmol/min and kAA ≈ 2× 10
14 l2/pmol2.
βT , kTL - Here we make use of the steady state relation given in equation (15),
as we have estimates for the parameters kT , kTA and kAI and we know the steady
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state value of plasma TAG, T ∗b , we can derive that
βT
1 + kTLI∗
= (kT + kTA(1 + kAII
∗))T ∗b ,
= 6× 10−3mmol/min. (25)
Now, as we have two parameters to find and only one equation we require a
little more information. Adiels et al. [15] carried out a study into the suppression
of hepatic VLDL1 secretion by insulin, and of particular use to us VLDL-TAG is
measured. This secretion of VLDL1 relates in our model to the release of TAG from
the liver; although the other types of lipoprotein are involved in TAG transport,
VLDL1 is responsible for the majority of the flux through the insulin inhibited
hepatic secretion pathway. Their study compared results for subjects with type-2
diabetes to control subjects under conditions of an euglycemic hyperinsulinemic
clamp following an overnight fast. Plasma insulin for the control subjects was
measured at approximately 50 pmol/l at the start of the clamp and 500 pmol/l once
a steady state was achieved. VLDL1-TAG secretion rate for the control subjects
was measured at approximately 250 mg/kg/day at the start of the clamp and 125
mg/kg/day once a steady state was reached. We can simplify this data by saying
that a 10 fold increase in plasma insulin, from its steady state value, causes hepatic
TAG output to drop to 50% of its steady state value. Combining this observation
with equation (25) gives a value for βT of 6.75× 10
−2 mmol/min and a value for
kTL of 2.5× 10
6 l/mmol.
5 Numerical Results
In this section we solve our model numerically subject to two different simulated
meals. Hence we must pick our input functions, FG(t) and FT (t), appropriately
and it will be useful for us to consider them in terms of energy (kcal).
The total amount of glucose entering the system from the diet is given by
Gin =
1
Vb
Z
∞
0
FG(t)dt. (26)
However as we are solving the nondimensional system we need to transform the
integral to nondimensional variables which gives
Gin = G
∗
b
Z
∞
0
bFG(bt)dbt. (27)
Now in order to convert this result from the units of our model, namely mmol/l
(blood), into energy we need to know the total volume of blood, the mass in grams
of one µmol of glucose and the amount of kcal per gram of glucose, which we will
denote by Vb, Rg and Cg respectively. This gives the following expression for total
energy from glucose entering the system from the diet
Gcal = CgRgVbG
∗
b
Z
∞
0
bFG(bt)dbt. (28)
Using a similar derivation for TAG entering the system from the diet gives
Tcal =
βTCtRtVbG
∗
b
βG
Z
∞
0
bFT (bt)dbt, (29)
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Table 3 List of parameters used to determine calorific content of simulated meal.
Parameter Description Value Reference
Vb Total volume of blood 5 l
Rg Mass of one mmol glucose 0.18 g [17, Ch. 6]
Cg Kcal per gram glucose 4 kcal [17, Ch. 6]
Rt Mass of one mmol TAG 0.85 g [17, Ch. 6]
Ct Kcal per gram TAG 9 kcal [17, Ch. 6]
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Fig. 5 Post-prandial kinetics for plasma glucose (top left), plasma insulin (bottom left),
plasma FFA (bottom right) and plasma TAG (top right) for a balanced meal (solid line)
and a high fat meal (dashed line). Time is plotted in hours.
where Rt and Ct denote the mass in grams of one mmol of TAG and the calories
per gram of TAG respectively. These parameters and their values are listed in
table 3.
Using the above results we simulate a “healthy” balanced meal and a high fat
meal and solve the model numerically in matlab. The initial conditions we take as
being the steady state after a 12–14 hour overnight fast. For the balanced meal we
choose the input functions to simulate a meal of 550 kcal carbohydrates (glucose)
and 150 kcal of fat (TAG). For the high fat meal we simulate 300 kcal of carbo-
hydrates and 300 kcal of fat. Before solving the governing equations numerically,
the system is nondimensionalised, the details of which are given in Appendix B.
The results for the plasma concentrations are shown in figure 5 and show good
qualitative agreement with experimental data, both in post prandial behaviour
and in the timescales to return to steady state [17, Ch. 6]. Only concentrations are
plotted here: since most fluxes are of the form constant times a concentration, the
evolution of fluxes simply follow the corresponding concentration. In Appendix C,
we plot more complex combinations of concentrations which describe the other
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Fig. 6 Experimental post-prandial kinetic data for plasma glucose (top left), plasma insulin
(lower left), plasma FFA (lower right), all plotted against time (hours). Taken from Taylor et
al. [12].
fluxes in the system. The quantitative agreement with experimental data for these
results is fairly good, as can be seen by comparing Figure 5 with the experimental
data of Taylor et al [12] plotted in Figure 6. Comparing the two meals we see that
plasma insulin and glucose concentrations do not reach as high in the high fat
meal as in the balanced meal, due to less glucose entering the system which also
directly affects the rate of insulin secretion. Plasma FFA has less of a decline in
the high fat meal due to the lower levels of insulin producing a smaller reduction
in the adipose tissue FFA output and plasma TAG concentration is higher in the
high fat meal.
The results for hepatic concentrations are shown in figure 7. Hepatic glycogen
shows good qualitative and quantitative agreement with experimental data [12].
Following ingestion of the meal glucose is taken up from the plasma to be stored
in the liver and within a few hours the liver is almost full to its maximum. Then
follows several hours of the store being slowly depleted as the glycogen is released
back into the plasma as glucose. Although we have no data to compare the results
for hepatic TAG with, these results seem to agree with our intuition, that following
a meal the liver TAG concentration would rise and then slowly deplete as the TAG
is released back into the plasma. The magnitude by which this happens is also in
agreement with the fact that liver fat content is not heavily affected by a single
meal but rather by a consistent unhealthy diet, which would result in a significant
build up of liver fat. Similarly, for the results for hepatic FFA, we have no data to
compare this to, however, the simulated results agree with our intuition. Following
ingestion of the meal, plasma FFA concentration decreases, this in turn causes the
hepatic FFA concentration to also decrease. Of particular interest is the simulated
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Fig. 7 Post-prandial kinetics for hepatic FFA (top left) hepatic TAG (top right) and hepatic
glycogen (lower left), for a balanced meal (solid line) and a high fat meal (dashed line). Ex-
perimental data for hepatic glycogen from Taylor et al. [12] is shown in the lower right plot.
In all plots, time is measured in hours.
“two stage” reduction in hepatic FFA which is due to the uptake and conversion
of plasma glucose into FFA in the liver partially counteracting the decrease in
concentration caused by the lower plasma FFA levels. Comparing the results for
the two meals we see that in the high fat meal, the shortage of glucose entering the
system means that hepatic glycogen does not reach its maximum after the meal
and over the course of the 12–14 hour simulation the liver has an overall net loss
of glycogen. The effects of the lower levels of plasma glucose and insulin can also
be seen in the results for hepatic FFA and TAG, with not enough glucose being
taken up into the liver and converted to FFA in order to see the two stage decline
in hepatic FFA. Interestingly we see that in the high fat meal the liver gains less
TAG and over the 12–14 hours actually loses TAG, this is due to the conversion
of hepatic FFA into TAG being an insulin driven pathway.
The results for skeletal muscle concentrations are shown in figure 8. We cur-
rently have no data to compare the results for all substrates in skeletal muscle
with. The results for skeletal muscle glucose and glycogen rise after ingestion of
the meal which would seem intuitive due to the increase in plasma glucose and
insulin. The results for skeletal muscle FFA and TAG show that, despite an el-
evated level of plasma TAG, the uptake of TAG from the plasma is not enough
to compensate for the reduced uptake of FFA from the plasma. Whether or not
this is what happens in vivo we are unable to say at this time as we have no data
to compare it to. In the case of the high fat meal we do however see that after
the initial decline in muscle FFA and TAG that we get a slight increase above the
steady state value, this is due to the timescale for appearance in, and subsequently
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Fig. 8 Post-prandial kinetics for muscle glucose (top left), muscle glycogen (bottom left),
muscle FFA (top right) and muscle TAG (bottom right) for a balanced meal (solid line) and
a high fat meal (dashed line), plotted against time (in hours).
removal from, the plasma of TAG being on a longer timescale than glucose and
insulin. There are data for metabolic flexibility in skeletal muscle for which we
can compare our model results to. There are well documented data for respiratory
quotient in skeletal muscle (∆RQ), these in effect measure how much of the total
oxidation in the muscle is due to glucose oxidation. We can define a term from our
model which is analogous to a respiratory quotient which we define by
SW =
MGPIGm
MAPAm +MGPIGm
=
MGIGm
MAAm +MGIGm
. (30)
The results for this “metabolic flexibility” are shown in figure 9. These results
show very good agreement with experimental data [8], with approximately one
third of oxidation being due to glucose oxidation in the fasted state and almost
90% of oxidation being due to glucose in the post prandial period in the case of
the balanced meal. As we would expect, in the case of the high fat meal we see
less of a switching in fuel source, however in the post prandial state glucose is still
the predominant fuel source.
One area that we simplify in our model which is of interest to us is the adipose
tissue. We do not take account of any concentrations inside adipose tissue nor do
we account for varying volumes of adipose tissue. We can however take some data
from our simulations to get an idea of the effect of the different meals on adipose
tissue by looking specifically at adipose tissue TAG uptake. We will produce the
results for adipose tissue TAG uptake in dimensional form by plotting the following
expression
kTA(1 + kAII
∗I)T ∗b Tb. (31)
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Fig. 9 Post prandial P (AMP) (top left) and post prandial adipose tissue TAG uptake (top
right) for a balanced meal (solid line) and a high fat meal (dashed line). Post-prandial metabolic
flexibility (lower left), assessed by the percentage of total oxidation due to glucose oxidation,
and experimental data on respiratory quotient, taken from Taylor et al. [12]. In all panels,
time is in hours. P , being a proxy for AMP, is left dimensionless.
The results for adipose tissue TAG clearance are shown in figure 9 and we can
see that following a meal some of the excess fat in the blood plasma is taken up into
the adipose tissue for storage. This rate is given by the product kTATb(1+ kAII),
and the form can be deduced from the graphs in Figure 5. In the case of the high
fat meal we can see there is a significant increase in the amount of fat taken up into
adipose tissue, despite the lower levels of plasma insulin and an overall lower total
calorific intake, due to the increased plasma TAG concentrations. In contrast, the
rate of triglyceride clearance in muscle is given by kDPPTm/(1 + kDII), whose
constituent concentrations can be seen in Figures 5 (I), 8 (Tm) and 9 (P ), from
these graphs we note that in the range 0 < t < 10 TAG clearance is higher during
high fat meal. Note, lower insulin levels during a high fat meal gives rise to the
counterbalancing possibility that high fat meals cause greater lipolysis of adipose
tissue.
6 Conclusions
We have developed a compartmental model of human metabolism including sub-
strate transport and utilisation in the plasma, the liver and skeletal muscle. Our
simulated results have been shown to be in good agreement with experimental
data, in particular the results for plasma concentrations and hepatic glycogen.
The fact that these are the substrates for which we can find many of the rate
parameters from the literature is encouraging. In the case of some of the rates,
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in particular those related to glucose and insulin, there is an abundance of data
available from the literature which implies that our modelling assumptions are
correct. We have stated that for some other results, although we currently have no
data to compare with, our model predictions agree with our intuition. In the case
of hepatic FFA and TAG we must be careful with how we assign these parameters
and what we define as intuitively correct, as the transport to and from, and the
conversion in, the liver are heavily dependent on what happens in the plasma. In
contrast to this, although we currently have little data on what happens in skeletal
muscle, this is not so important since the equations for plasma and hepatic con-
centrations have no dependence on the skeletal muscle concentrations. In effect,
we really have two subsystems, the plasma-liver subsystem and the skeletal muscle
subsystem, which is driven by the plasma-liver subsystem.
In recent years there has been much mathematical modelling of human metab-
olism, however, most of this work focuses on smaller scale, localised modelling,
describing in detail certain systems or pathways involved with metabolism and
in some cases focusing on kinetics on the cellular level. In this paper we have
taken a larger scale approach to modelling metabolism and derived equations to
link together most of the different pathways involved with metabolism of carbo-
hydrates and fats by taking a less detailed approach but still keeping account of
the important stages in metabolism. The model does not model the increase or
decrease in adipose tissue over large times, it is not designed to describe the long
term starvation. Rather, our aim is to provide a more detailed understanding of
metabolic flexibility.
We developed a system of 12 first-order coupled differential equations which
describe human metabolism across the whole body. With important tissues such as
the liver and skeletal muscle modelled in detail and the rest of the body simplified
into single terms. We found steady state solutions to the system and used these
solutions to nondimensionalise the system which reduces the number of parameters
which influence the models kinetic behaviour. We found numerical results for the
model based on ingestion of a ”balanced” meal and highlighted areas where our
model results are in agreement with experimental data as well as areas where we
are unsure of the physiological behaviour due to a lack of data.
Future work on this model will include calibrating the model to simulate
insulin-resistance in order to produce a variety of results for different levels of
insulin resistance, different combinations of tissues insulin resistant. We shall also
look at different combinations of meals and meal compositions. In addition, we
plan to expand the model to give a more complete model of human metabolism by
including a more detailed study AMP oxidation, lactate transport between skele-
tal muscle and the liver, gluconeogenesis in the liver, including other regulatory
hormones (such as glucagon) and modelling metabolism in adipose tissue [48].
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A Properties of solutions of the governing equations
A.1 Uniqueness of Steady State
In this appendix we will prove the uniqueness of our steady states. We begin by writing down
which variables each steady state is a function of (except I∗),
G∗b =
βG
(1 + kGLI∗
2)(SG + kG(1 + kGII∗) + kLI∗ + kALI∗)
= f1(I
∗),
T ∗b =
βT
(1 + kTLI∗)(kTA(1 + kAII∗) + kT )
= f2(I
∗),
A∗l =
kALI
∗G∗b + kBLA
∗
b
SL
1+kASI
∗
+ kLB + kTHI∗
= f3(I
∗, G∗b , A
∗
b ),
A∗b =
βA
(1 + kAAI∗
2)(kA + kBL)
+
kLBA
∗
L
kA + kBL
= f4(I
∗, A∗l ),
G∗m =
βGkG(1 + kGII
∗)
MGP ∗I∗(SG + kG(1 + kGII∗) + kLI∗ + kALI∗)
= f5(I
∗, P ∗),
A∗m =
1
MAP ∗
„
βT kT
(1 + kTLI∗)(kTA(1 + kAII∗) + kT )
«
= f6(I
∗, P ∗),
Y ∗m = kY G
∗
m
„
1 + kY II
∗
1 + kY PP ∗
«„
1 + kCII
∗
kCPP ∗
«
= f7(I
∗, P ∗, G∗m),
T ∗m = kXA
∗
m
„
1 + kXII
∗
1 + kXPP ∗
«„
1 + kDII
∗
kDPP ∗
«
= f8(I
∗, P ∗, A∗m),
P ∗ =
µ− µc
λP
= f9(I
∗). (32)
The expressions for A=b f4 and A
∗
l = f3 form a linear system for A
∗
b and A
∗
l which has a unique
solution for each quantity in terms of I∗ and G∗b , and hence the solutions can be written
explicitly in terms of I∗ using G∗b = f1(I
∗). Now we substitute the expression for P ∗ = f9
into the equations for G∗m = f5, A
∗
m = f6, Y
∗
m = f7, etc. to obtain a simpler system given by
G∗b = f1(I
∗), T ∗b = f2(I
∗), A∗l =
ef3(I∗), A∗b = ef4(I∗), G∗m = ef5(I∗),
A∗m =
ef6(I∗), Y ∗m = ef7(I∗, G∗m), T ∗m = ef8(I∗, A∗m), P ∗ = f9(I∗). (33)
Thus all quantities can now be written as a function of I∗, only T ∗m still depend on other
quantities, and these can be eliminated using other expressions in (33), for example, T ∗m =
f˜8(I∗, f˜6(I∗)).
Considering the steady-state equation for insulin, we write down an expression for I∗,
I∗ =
k1 + k2erf((Gb − v)/c) + kIAA
∗
b
λI
. (34)
We now examine the steady state values for G∗b and A
∗
b given in table 2 and note that Gb terms
contribute more significantly to the steady state than the A∗b terms. Hence we temporarily
neglect the A∗b term. Under this assumption we substitute in the expression for G
∗
b to find
λII
∗ = k1 + k2erf
„
f1(I∗)− v
c
«
.
The left hand side of equation 35 is an increasing function of I∗ for I∗ > 0, satisfying rhs= 0
when I∗ = 0, and the right hand side is a decreasing function of I∗ for I∗ > 0, with rhs> 0
at I∗ = 0; therefore there is a unique solution for I∗.
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Given that I∗ has a unique solution, we can now follow the chain of reasoning
I∗ has unique steady-state ⇒ G∗b , T
∗
b , P
∗ have unique steady-states,
I∗ and P ∗ have unique steady-states ⇒ G∗mandA
∗
m have unique steady-states,
I∗ and G∗b have unique steady-states ⇒ Al ∗ and A
∗
b have unique steady-state ,
I∗, P ∗ and G∗m have unique steady-states ⇒ Y
∗
m has unique steady-state ,
I∗, P ∗ and A∗m have unique steady-states ⇒ T
∗
m has unique.
Hence the system as whole has a unique steady-state solution.
Reinstating the A∗b term theoretically could make the rhs of (35) nonmonotone, and so
there could be multiple steady-states, however, for the physically realistic parameter values of
interest to us, this does not occur.
A.2 Positivity of solutions
Since all of the governing equations (1)–(4), (7)–(14) have the form dX/dt = A − BX with
A > 0, we can be sure that if X = 0 ever occurs, then X would increase, and so, provided we
start with positive initial data, the concentrations will remain positive for all time.
Since the nonlinearities in the model are all analytic and have at most linear growth,
the standard theory of ordinary differential equations implies uniqueness for the initial value
problem.
B Non-dimensionalisation
Before we attempt to solve the system numerically, we nondimensionalise it so that we may
reduce the number of parameters in the model. This process also allows for simpler numerical
simulations. We rescale each variable by its steady state value, except for YL which we rescale
by Ymax, and TL which we rescale by a typical healthy liver fat concentration, denoted by
THL . This means that we are now concerned with the following non-dimensional variables
bYL = YL
Ymax
, bAL = AL
A∗L
, bTL = TL
THL
, bGb = Gb
G∗b
,
bAb = Ab
A∗b
, bTb = Tb
T ∗b
, bI = I
I∗
, bGm = Gm
G∗m
, bYm = Ym
Y ∗m
,
bYm = Ym
Y ∗m
, bAm = Am
A∗m
, bTm = Tm
T ∗m
, bP = P
P ∗b
, t =
VbG
∗
B
βG
bt.
The forcing functions are nondimensionalised by FG(t) = βG bFG(bt) and FT (t) = βT bFT (bt),
where the nondimensional forcing functions are given by
bFG(bt) = bkFGbtbτG e−bt
2/2bτ2
G , bkFG = θG
BGβG
, bτG = BGβG
VbG
∗
B
, (35)
bFT (bt) = bkFTbtbτT e−bt
2/2bτ2
T , bkFT = θT
BT βT
, bτT = BT βG
VbG
∗
B
, (36)
In terms of their non-dimensional variables the functions f1, f2 and f3 are given by
f1(bYL) = bYL
Yc + bYL , Yc =
Y0
Ymax
,
f2(bYL) = 1− bYL
Yc + 1− bYL , Yc =
Y0
Ymax
,
f3(bTL) = bTL
Tc + bTL , Tc =
T0
THL
. (37)
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Using the above rescalings we obtain the following system of nondimensional equations where
we have dropped the hats for convenience
η
dYL
dt
= ψL
„
β1IGbf2(YL) +
f1(YL)
1 + δGI2
«
, (38)
η
dAL
dt
= ǫgaθ1IGb −
„
θ3
1 + δHI
+ θ2 + θ4I
«
AL +
θ5
ǫlb
Ab, (39)
η
dTL
dt
= ǫatθ4IAL −
ψV f3(TL)
1 + δT I
, (40)
dGb
dt
= FG(t) +
f1(YL)
1 + δGI2
−
Gb
1 + δG
+ β1(1− If2(YL))Gb
+(β0 + θ1)(1 − I)Gb, (41)
dAb
dt
= ψa
„
1
1 + δAI2
−
Ab
1 + δA
«
+ ǫlbθ2(AL − Ab), (42)
dTb
dt
= ψt
„
FT (t) +
f3(TL)
1 + δT I
−
Tb
1 + δT
«
+ (β4 + β5)(1 − I)Tb, (43)
dI
dt
= β6(1− I) + β7(Ab − I) + β8(erf(wGb − ρ)− Ierf(w − ρ)), (44)
α
dGm
dt
= µg(Gb − PIGm)− ǫggβ0Gm(1 − I)
−ǫygβ2
„
(1 + γp)
(1 + γpP )
(1 + γyI)
(1 + γy)
Gm
«
− ǫygβ2
„
(1 + γI )
(1 + γII)
PYm
«
, (45)
α
dAm
dt
= µa(Ab − AmP )− ǫtaβ4(Ab − Tb) + ǫtaβ4γt(Ab − ITb)
−ǫtgβ3
„
(1 + γq)
(1 + γqP )
(1 + γxI)
(1 + γx)
Am
«
− ǫtgβ3
„
(1 + γj)
(1 + γjI)
PTm
«
, (46)
α
dYm
dt
= β2
„
(1 + γp)
(1 + γpP )
(1 + γyI)
(1 + γy)
Gm
«
− β2
„
(1 + γI )
(1 + γII)
PYm
«
, (47)
α
dTm
dt
= β3
„
(1 + γq)
(1 + γqP )
(1 + γxI)
(1 + γx)
Am
«
− β3
„
(1 + γj)
(1 + γjI)
PTm
«
, (48)
α
dP
dt
= µp(1− P ) + ǫgpγgµgP (1− IGm) + ǫapγaµaP (1− Am). (49)
where the new dimensionless parameters are given by
β0 =
kGkGII
∗G∗b
βG
, β1 =
kLI
∗G∗b
βG
, β2 =
kCPP
∗G∗b
βGG∗m(1 + kCII
∗)
, ρ =
v
c
, w =
G∗b
c
,
β3 =
kDPP
∗G∗b
βGA∗m(1 + kDII
∗)
, β5 =
kTAI
∗G∗b
βG
, β4 =
kT I
∗G∗b
βG
, β6 =
k1G∗b
βGI∗
,
β7=
kIAA
∗
bG
∗
b
βGI∗
, β8=
k2G∗b
βGI∗
, θ1=
kALI
∗G∗b
βG
, θ2=
kLBG
∗
b
βG
, θ3=
SLG
∗
b
βG
,
θ4 =
kTHI
∗G∗b
βG
, θ5 =
kBLG
∗
b
βG
, γY = kY II
∗, γP = kY P I
∗, γQ = kXP I
∗,
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γI = kCII
∗, γJ = kDII
∗, γX = kXII
∗, µp =
µG∗b
βGP ∗
, µg =
MGP
∗I∗G∗b
βG
,
µa =
MAP
∗G∗b
βG
, ψL =
G∗b
Ymax
, ψa =
βAG
∗
b
βGA
∗
b
, ψT =
βTG
∗
b
βGT
∗
b
, ψV =
βTG
∗
b
βGT
H
L
,
δG = kGLI
∗2, δT = kTLI
∗, δA = kAAI
∗2, δH = kASI
∗, ǫga =
G∗b
A∗L
,
ǫlb =
A∗L
A∗b
, ǫgg =
G∗b
G∗m
, ǫyg =
Y ∗m
G∗m
, ǫta =
T ∗b
A∗m
, ǫat =
A∗L
THL
, ǫgp =
G∗m
P ∗
,
ǫap =
A∗m
P ∗
, ǫtg =
T ∗m
G∗m
, α =
Vs
Vb
, η =
Vl
Vb
, Yc =
Y0
Ymax
, Tc =
T0
THL
. (50)
The values for the nondimensional parameters are given in table 4.
C Graphs of fluxes
In this section we plot various combinations of the governing concentration variables to il-
lustrate the evolution of the fluxes in the model. Noting that the three functions f1, f2, f3
are defined to be unity over the vast majority of their ranges, we only need to consider 10
combinations of concentrations of functions, which are plotted in Figures 10 and 11.
The flux of glucose from plasma to muscle has a component which depends on insulin
according to the product IGb, which we plot in the top left panel of Figure 10. This quantity
also influences the flux from plasma glucose to liver glycogen and liver FFA, see equations (2),
(7), (8), and (11). The flux from plasma TAG to adipose tissue as modelled in (3) depends
on the product ITb, which is plotted in the top central panel. This is the only case where the
high fat meal induces a higher response than the balanced meal. The product IAL describes
the rate of conversion of FFA into TAG in the liver (8)–(9).
In the muscle, both glucose and FFA are used to convert P into ATP, with rates that
depend on PIGm and PAm respectively, as described by equations (10), (11) and (13). These
two fluxes are plotted in the lower left and lower centre plots in Figure 10. The difference be-
tween balanced and high fat meals is more pronounced in the glucose term than the FFA term.
The product PTm determines the rate of conversion of TAG to FFA in muscle as described in
equations (13) and (14), (note that in our current parameterisation, kDI = 0).
In the top left panel of Figure 11, we plot the rate of release of glucose into the plasma
from liver glycogen, this is inhibited by insulin, which we have modelled by βG/(1 + kGLI
2)
in equations (2) and (7). The top right panel shows the flow of FFA from adipose tissue to
plasma, which has a similar form, but with kAA replacing kGL, see equation (4). The flux from
liver TAG to plasma TAG is shown in the lower left panel. This has weaker insulin dependence,
being of the form βT /(1 + kTLI) in equations (3) and (9). The oxidation of hepatic FFA is
shown in the lower right panel of Figure 11, this has the form SLAL/(1+ kASI), see equation
(8). All four fluxes show significant reductions for the time that insulin is elevated, and not a
great difference between the high fat mean and the balanced meal.
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